GSK building S$50M drug technology center in Singapore

4 July 2004

UK-headquartered drug giant GlaxoSmithKline is building a S$50 million($29.2 million) drug technology center that will double the firm's laboratory space in Singapore, reports the local Business Times. The announcement came during the opening of a new S$100 million extension at GSK's Jurong site, it was noted, and the new project will bring the group's total investment in Singapore to S$1 billion. The newly-completed site will manufacture the firm's asthma drug fluticasone propionate.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight